S100A14 in Tumor‐Derived EVs Targets PIAS3 to Reprogram Astrocytes and Induce Immunosuppressive Microenvironment Promoting Brain Metastasis and Germacrone Reversal Effect
Source abstract
Abstract
ABSTRACT Brain metastasis (BrM) is the most common complication with the highest mortality in clinical tumor patients. Its underlying pathogenesis remains unclear, and effective therapeutic compounds are currently unavailable. Herein, we first revealed that S100A14 is a critical molecular mediator of tumor‐derived exosomes (EVs)‐driven BrM. DIA‐based proteomics demonstrated consistently high S100A14 expression in BrM‐EVs from both cells (53.2‐fold in A549 BM3 cells and 2.4‐fold in 4T1 BM2 cells) and clinical patient samples (5.1‐fold). Intracardiac injection mice model confirmed that S100A14‐overexpression EVs promoted BrM in breast (4T1: 88.89% vs. 44.45%; MDA‐MB‐231: 66.67% vs. 33.33%) and lung cancer (LLC: 50% vs. 33.33%; A549: 83.33% vs. 33.33%). Mechanistically, S100A14 directly targeted PIAS3 to reprogram astrocytes (AS) by activating STAT3 signaling and triggering secretion of pro‐inflammatory chemokines (CCL2/CCL5/CXCL5), which recruit immunosuppressive MDSCs. Crucially, we identified the natural compound, germacrone, as a promising therapeutic agent that effectively inhibited BrM progression in both lung and breast cancer without significant toxicity. Germacrone directly binds to S100A14 in AS to disrupt the S100A14‐PIAS3 interaction, inhibit STAT3 activation, and MDSCs recruitment. Our study elucidated a novel mechanism by which tumor‐derived S100A14 EVs promote tumor BrM. Moreover, germacrone emerged as a prospective therapeutic agent for preventing BrM by specifically targeting S100A14.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: S100 Proteins and Annexins · Extracellular vesicles in disease · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Guangdong Provincial Key Laboratory of Translational Chinese Medicine, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines International Institute for Translational Chinese Medicine School of Pharmaceutical Sciences Guangzhou University of Chinese Medicine Guangzhou China
Department of Neurosurgery the Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
Funding
National Key Research and Development Program of China
References (52)
Show source-provided references
1. 10.1038/s41586‐022‐05680‐310.1038/s41586‐022‐05680‐3 ↗
2. 10.1038/s41568‐019‐0220‐y10.1038/s41568‐019‐0220‐y ↗
3. 10.1016/j.trecan.2018.01.00310.1016/j.trecan.2018.01.003 ↗
4. 10.1186/s13046‐025‐03315‐910.1186/s13046‐025‐03315‐9 ↗
5. 10.1186/s12987‐025‐00618‐z10.1186/s12987‐025‐00618‐z ↗
6. 10.1016/j.tranon.2025.10228710.1016/j.tranon.2025.102287 ↗
7. Cancer Cell‐derived Migrasomes Harboring ATF6 Promote Breast Cancer Brain Metastasis via Endoplasmic Reticulum Stress‐mediated Disruption of the Blood‐brain Barrier
8. 10.1038/s41572‐018‐0055‐y10.1038/s41572‐018‐0055‐y ↗
9. 10.1186/s43556-025-00251-010.1186/s43556-025-00251-0 ↗
10. 10.1016/j.gendis.2023.10117510.1016/j.gendis.2023.101175 ↗
11. 10.1016/j.jconrel.2025.01.03310.1016/j.jconrel.2025.01.033 ↗
12. 10.1186/s12974‐019‐1538‐910.1186/s12974‐019‐1538‐9 ↗
13. Complement C3 of Tumor‐derived Extracellular Vesicles Promotes Metastasis of RCC via Recruitment of Immunosuppressive Myeloid Cells
14. 10.1186/s13046‐020‐01688‐710.1186/s13046‐020‐01688‐7 ↗
15. 10.1186/s12951-024-02414-710.1186/s12951-024-02414-7 ↗
16. 10.1016/j.devcel.2023.01.00610.1016/j.devcel.2023.01.006 ↗
17. 10.1016/j.jconrel.2023.10.00710.1016/j.jconrel.2023.10.007 ↗
18. 10.1038/s41467-025-64149-910.1038/s41467-025-64149-9 ↗
19. 10.1007/s10555‐025‐10276‐010.1007/s10555‐025‐10276‐0 ↗
20. 10.1016/j.canlet.2025.21787010.1016/j.canlet.2025.217870 ↗
21. 10.1016/j.canlet.2022.21572610.1016/j.canlet.2022.215726 ↗
22. 10.1016/j.canlet.2024.21726210.1016/j.canlet.2024.217262 ↗
23. 10.1016/j.jconrel.2022.07.00910.1016/j.jconrel.2022.07.009 ↗
24. 10.1093/neuonc/noae01310.1093/neuonc/noae013 ↗
25. 10.1038/s41698‐025‐00833‐910.1038/s41698‐025‐00833‐9 ↗
26. 10.1002/advs.20230634810.1002/advs.202306348 ↗
27. 10.1016/j.molmed.2018.07.00210.1016/j.molmed.2018.07.002 ↗
28. 10.1158/2159‐8290.CD‐24‐149510.1158/2159‐8290.CD‐24‐1495 ↗
29. 10.1002/ctm2.178610.1002/ctm2.1786 ↗
30. 10.1016/j.phrs.2023.10691510.1016/j.phrs.2023.106915 ↗
31. 10.1182/bloodadvances.202100456210.1182/bloodadvances.2021004562 ↗
32. 10.1002/advs.20250705410.1002/advs.202507054 ↗
33. 10.1038/s41388‐020‐1363‐810.1038/s41388‐020‐1363‐8 ↗
34. 10.1186/s12967‐024‐05994‐y10.1186/s12967‐024‐05994‐y ↗
35. 10.1016/j.canlet.2022.21583310.1016/j.canlet.2022.215833 ↗
36. 10.1136/gutjnl‐2024‐33290110.1136/gutjnl‐2024‐332901 ↗
37. 10.1111/acel.1439310.1111/acel.14393 ↗
38. 10.1038/s41419‐022‐04825‐610.1038/s41419‐022‐04825‐6 ↗
39. 10.1016/j.ymthe.2023.09.01010.1016/j.ymthe.2023.09.010 ↗
40. 10.2147/CMAR.S25052210.2147/CMAR.S250522 ↗
41. 10.2174/011871520631232424080507505010.2174/0118715206312324240805075050 ↗
42. 10.1021/acs.analchem.1c0007110.1021/acs.analchem.1c00071 ↗
43. 10.1016/j.ab.2014.02.01110.1016/j.ab.2014.02.011 ↗
44. 10.1006/meth.1999.092410.1006/meth.1999.0924 ↗
45. 10.1039/D2AN00824F10.1039/D2AN00824F ↗
46. 10.1021/acsnano.4c1457310.1021/acsnano.4c14573 ↗
47. 10.1002/advs.20231026610.1002/advs.202310266 ↗
48. 10.3389/fphar.2025.154733310.3389/fphar.2025.1547333 ↗
49. 10.1136/gutjnl‐2020‐32301410.1136/gutjnl‐2020‐323014 ↗
50. 10.7150/ijbs.8676710.7150/ijbs.86767 ↗
51. 10.1016/j.addr.2021.11396110.1016/j.addr.2021.113961 ↗
52. 10.1038/s43587‐024‐00727‐810.1038/s43587‐024‐00727‐8 ↗